Alex Duncan
Company: Walden Biosciences
Job title: Chief Scientific Officer
Seminars:
Proteomic Insights Into Causality & WAL0921 Treatment Effects in suPARDriven CKD 2:30 pm
Further evidence for suPAR driven progression in rare kidney disease indications WAL0921 as a suPAR reducing agent in kidney therapy Proteomic data insights into mechanism of action of anti-suPAR treatmentRead more
day: Conference Day One